LEXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lexaria Bioscience Corp (LEXX) is not a good buy for a beginner, long-term investor at this time. The company's financial performance is significantly deteriorating, technical indicators are bearish, and there are no positive catalysts or strong trading signals to support an immediate investment. Additionally, the analyst has lowered the price target, reflecting weaker confidence in the stock's potential.
The stock is showing bearish technical indicators. The MACD histogram is negative and expanding downward, the RSI is neutral but leaning toward oversold territory, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 0.708, with key support at 0.636 and resistance at 0.781.
NULL identified. No recent news or significant events to act as a positive catalyst.
The company's financial performance has significantly declined in Q1 2026, with revenue dropping to 0, net income falling by 41.01% YoY, and EPS declining by 56.25%. Additionally, the analyst has lowered the price target from $4 to $1.50, citing weaker-than-expected performance in a recent study.
In Q1 2026, the company reported a 100% YoY revenue drop to 0, a 41.01% YoY decline in net income to -$1,595,007, and a 56.25% YoY drop in EPS to -0.07. Gross margin also fell to 0, indicating no profitability.
H.C. Wainwright analyst Yi Chen lowered the price target from $4 to $1.50 but maintained a Buy rating. The downgrade reflects weaker performance in a recent study compared to expectations.
